Pharmaceutical - Victoza, Research

Filter

Current filters:

VictozaResearch

Popular Filters

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop

14-06-2013

Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial

24-05-2013

Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Positive new Ph III data on Novo Nordisk's Victoza

28-11-2012

Global Denmark-based insulin giant Novo Nordisk (NOV: N) yesterday reported data from two Phase IIIb…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results

08-11-2012

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal

23-04-2012

Danish diabetes specialist Novo Nordisk (NOV: N) says that its investigational ultra-long-acting insulin…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk

10-04-2012

The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Back to top